Clinical Utility of Serum Periostin as Biomarker of Differential Diagnosis for Different Phenotypes of Bronchial Asthma
Serum Periostin as Biomarker for the Diagnosis of Asthma
Keywords:Asthma, Phenotypes, T2 disease, Non-T2 disease, Periostin, Atopy, Eosinophils, Th2 Inflammation
Periostin is a protein produced from epithelial cells of the respiratory tract in response to the stimulation from IL-I3. Periostin levels in serum are associated with its production in airways. This study was conducted to evaluate the clinical utility of serum periostin levels in the differential diagnosis of atopic and non-atopic asthma. This cross-sectional comparative study was carried out at Medsol Clinical Laboratory, Islamabad on 40 healthy individuals as control (Group A) and 40 asthmatic patients (Group B) from Jan-2020 to Aug-2020. Group B was comprised of 20 atopic asthmatic patients (Group BI) with positive skin prick test and 20 non-atopic asthmatic patients (Group BII) with negative skin prick test. Demographic data were obtained on proforma, lung function test and skin prick test was performed at pulmonologist clinic. EDTA and clotted blood samples were obtained from all participants to measure absolute eosinophil count (AEC) and periostin levels. Serum periostin levels were significantly higher in asthmatic patient Group B (396 ± 84) than healthy controls Group A (185 ± 40). In asthmatic groups, serum periostin levels were significantly higher in group BI (atopic asthmatic) than group B II (non-atopic asthma). There was a strong association between serum periostin and AEC (0.83), serum periostin, and FEV1 (-0.81) in atopic asthmatic patients. We concluded that serum periostin can be used for the diagnosis of bronchial asthma and a good purposed biomarker for differential diagnosis of different phenotypes of asthma.
H.M. Rashid., M. Khan., M. Jamal, and W. Shah. Anemia in Asthmatic Females Exaggerates the Severity of Inflammation in Asthma by Inducing Dyslipidemia, High levels of IgE and Absolute Eosinophil count. Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences 56(2):1–6 (2019).
A. Fuhlbrigge., D. Peden., A.J. Apter., H.A. Boushey., C.A. Camargo Jr., J. Gern., P.W. Heymann., F.D. Martinez., D. Mauger., W.G. Teague, and C. Blaisdell. Asthma outcomes: exacerbations. Journal of Allergy and Clinical Immunology 129(3): 34-48(2012).
P.A. LOFTUS, and S.K. WISE. Epidemiology of asthma. Current opinion in otolaryngology & head and neck surgery 24(3): 245-249 (2016).
A. Vianello., M. Caminati., M. Andretta., A. Menti., S. Tognella., G. Senna, and L.D. Esposti. Prevalence of severe asthma according to the drug regulatory agency perspective. An Italian experience. The World Allergy Organization Journal 12(4): (2019).
M.E. Kuruvilla., F.E.H. Lee, and G.B. Lee. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clinical reviews in allergy & immunology 56(2): 219-233( (2019). Serum Periostin as Biomarker for the Diagnosis of Asthma 11
A. Edris., H.T.D. Dekker., E. Melén, and L. Lahousse). Epigenome‐wide association studies in asthma. A systematic review. Clinical & Experimental Allergy 49(7): 953-968 (2019).
T.G. Kormelink., M. Thio., B.R. Blokhuis., F.P. Nijkamp, and F.A. Redegeld. Atopic and nonatopic allergic disorders. Current insights into the possible involvement of free immunoglobulin light chains. Clinical & Experimental Allergy 39(1): 33-42(2009).
W. Li., P. Gao., Y. Zhi., W. Xu., Y. Wu., J. Yin, and L. Zhang. Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respiratory research 16(1): 1-10( 2015).
G. Jia, R.W. Erickson., D.F. Choy., S Mosesova., L.C. Wu., O.D. Solberg., A. Shikotra., R. Carter., S. Audusseau.,Q. Hamid, and P. Bradding. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. Journal of Allergy and Clinical Immunology130(3):647-654(2012).
L.K. Rosselli., Murai., L.O. Almeida., C. Zagni., P.G. Moreno., M. P. Molina., S.L. Volk.,M. J. Murai., H.F. Rios., C. H. Squarize, and R.M. Castilho. Periostin responds to mechanical stres s and tension by activating the MTOR signaling pathway. PloS one 8(12): 83580. (2013)
E.D. Gordon., S.S. Sidhu., Z.W. Wang., P.G. Woodruff., S. Yuan., M.C. Solon., S.J. Conway., X. Huang., R.M. Locksley, and J.V. Fahy. A protective role for periostin and TGF‐β in IgE‐mediated allergy and airway hyperresponsiveness. Clinical & Experimental Allergy 42(1): 144-155( 2012).
J.K. Bentley.,Q. Chen., J. Y. Hong., A. P. Popova., J. Lei., B.B. Moore, and M.B. Hershenson. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. Journal of allergy and clinical immunology 134(6):1433-1442( 2014)
Y. Kanemitsu., I. Ito., A. Niimi., K. Izuhara., S. Ohta., J. Ono., T. Iwata., H. Matsumoto, and M. Mishima. Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. American journal of respiratory and critical care medicine 190(4): 472-474 (2014)
R. Rasool., I.A. Shera., S. Nissar., Z.A. Shah., N. Nayak., M. A. Siddiqi, and A. S. Sameer. Role of skin prick test in allergic disorders: a prospective study in kashmiri population in light of review. Indian journal of dermatology 58(1):12-16 (2013)
H. Fuseini. and D.C. Newcomb. Mechanisms driving gender differences in asthma. Current allergy and asthma reports 17(3): 1-9.( 2017)
D. Norbäck., C. Lu., L. Wang., Y. Zhang., B. Li.,Z. Zhao., C. Huang., X. Zhang., H. Qian., Y. Sun, and J. Sundell. Asthma and rhinitis among Chinese children—indoor and outdoor air pollution and indicators of socioeconomic status (SES). Environment international 1151:(2018)
T. Inoue.,K. Akashi., M. Watanabe.,Y. Ikeda., S. Ashizuka., T. Motoki., R. Suzuki., N. Sagara., N. Yanagida., S. Sato, and M. Ebisawa,. Periostin as a biomarker for the diagnosis of pediatric asthma. Pediatric Allergy and Immunology 27(5): 521-526 (2016).
D. R. Mohammed., A.Y. Abdelnaby.,E.A. El Zamran, and I.S. Ibrahim. Role of serum periostin as a biomarker in diagnosis of bronchial asthma.The Egyptian Journal of Chest Diseases and Tuberculosis 67(1): 4-8(2018).
R.J. Arnold., M. Massanari., T.A. Lee, and E. Brooks. A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (FeNO) in asthma management. Manag Care 27(7): 34-41 (2018).
T.F. Carr., A.A. Zeki, and M. Kraft,,. Eosinophilic and noneosinophilic asthma. American journal of respiratory and critical care medicine 197(1): 22-37(2018).
J.V. Fahy. Type 2 inflammation in asthma—present in most, absent in many. Nature Reviews Immunology, 15(1) : 57-65 (2015)